Cargando…

Monitoring PD-L1 Expression on Circulating Tumor–Associated Cells in Recurrent Metastatic Non–Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy

Current diagnostic methods to determine programmed death 1 (PD-1) receptor and its ligand (PD-L1)/PD-1 immunotherapy (immune checkpoint inhibitor [ICI]) efficacy in recurrent or metastatic non–small-cell lung carcinoma (rmNSCLC) are imprecise. Although previously shown that patients with high tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moran, Jillian A., Adams, Daniel L., Edelman, Martin J., Lopez, Pablo, He, Jianzhong, Qiao, Yawei, Xu, Ting, Liao, Zhongxing, Gardner, Kirby P., Tang, Cha-Mei, Lin, Steven H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2022
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166406/ https://www.ncbi.nlm.nih.gov/pubmed/36516370 http://dx.doi.org/10.1200/PO.22.00457

Ejemplares similares

Beta 2-Adrenergic Receptor in Circulating Cancer-Associated Cells Predicts for Increases in Stromal Macrophages in Circulation and Patient Survival in Metastatic Breast Cancer
por: Gardner, Kirby P., et al.
Publicado: (2022)

Circulating stromal cells in resectable pancreatic cancer correlates to pathological stage and predicts for poor clinical outcomes
por: Gardner, Kirby P., et al.
Publicado: (2021)

In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
por: Babačić, Haris, et al.
Publicado: (2020)

Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy
por: Herbreteau, Guillaume, et al.
Publicado: (2018)

Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
por: Serratì, Simona, et al.
Publicado: (2022)

Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study
por: Herbreteau, Guillaume, et al.
Publicado: (2021)

Cancer associated macrophage-like cells and prognosis of esophageal cancer after chemoradiation therapy
por: Gironda, Daniel J., et al.
Publicado: (2020)

CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome
por: Raghavakaimal, Ashvathi, et al.
Publicado: (2022)

Circulating CD137(+) T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2022)

Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy
por: Strati, Areti, et al.
Publicado: (2023)

PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer
por: Darga, Elizabeth P., et al.
Publicado: (2021)

Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells
por: Lian, Shu, et al.
Publicado: (2019)

Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer
por: Dhar, Manjima, et al.
Publicado: (2018)

Enumeration and molecular characterization of circulating tumor cells enriched by microcavity array from stage III non-small cell lung cancer patients
por: Cohen, Evan N., et al.
Publicado: (2020)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
por: Shi, Guilan, et al.
Publicado: (2022)

Circulating memory PD-1(+)CD8(+) T cells and PD-1(+)CD8(+)T/PD-1(+)CD4(+)T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients
por: Liu, Jiang, et al.
Publicado: (2023)

Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers
por: Kong, Yuehong, et al.
Publicado: (2021)

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021)

Research progress on dendritic cell vaccines in cancer immunotherapy
por: Yu, Jifeng, et al.
Publicado: (2022)

Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy and Stereotactic Radiation Therapy or Immunotherapy Alone: A National Cancer Database Analysis
por: Piening, Alexander, et al.
Publicado: (2023)

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy
por: Dupuis, Frantz, et al.
Publicado: (2018)

Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: The Current and Future Role of Radiation Therapy in the Era of Immunotherapy
por: Ferini, Gianluca, et al.
Publicado: (2022)

Extracorporeal Photo-Immunotherapy for Circulating Tumor Cells
por: Kim, Gwangseong, et al.
Publicado: (2015)

Emerging role of circulating tumor cells in immunotherapy
por: Rzhevskiy, Alexey, et al.
Publicado: (2021)

Use of Immunotherapy and Radiation Treatment in the Management of Metastatic Melanoma With Rhabdomyosarcomatous Differentiation
por: Gupta, Apar, et al.
Publicado: (2019)

Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
por: Clancy, Kate, et al.
Publicado: (2021)

Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer
por: Ren, Yifan, et al.
Publicado: (2022)

Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer
por: Arasanz, Hugo, et al.
Publicado: (2022)

Novel immunotherapy in metastatic renal cell carcinoma
por: Cho, Yang Hyun, et al.
Publicado: (2017)

Combining Radiation- with Immunotherapy in Prostate Cancer: Influence of Radiation on T Cells
por: Lindner, Diana, et al.
Publicado: (2022)

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
por: Yao, Han, et al.
Publicado: (2018)

Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Patient With Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review
por: Zhao, Xiangrong, et al.
Publicado: (2020)

Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review
por: He, Haihua, et al.
Publicado: (2021)

FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
por: Flaus, A., et al.
Publicado: (2021)

Exceptional response to PD-1 inhibition immunotherapy in advanced metastatic osteosarcoma with tumor site infection
por: Li, Meng, et al.
Publicado: (2022)

Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy
por: Papadaki, Maria A, et al.
Publicado: (2020)

Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid
por: Portnow, Jana, et al.
Publicado: (2020)

PD-1(+) mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
por: Li, Jun, et al.
Publicado: (2022)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borel, Christian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lte7i776co23jcqib4icnv6ohk